Search

Ya sea que le hayan diagnosticado un tipo de cáncer poco común u otro más común, los médicos de MSK pueden brindarle una segunda opinión.

… Thursday, December 18, 2025 Enterarse de que tiene cáncer puede ser una experiencia abrumadora. Al comenzar a investigar cómo proceder luego de recibir un  diagnóstico de cáncer , probablemente escuche hablar mucho de una segunda opinión. Memorial Sloan Kettering Cancer Center (MSK) da segundas opiniones

Paige Arnold, who will graduate from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) next spring, has been awarded the 2022 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Emeritus Louis V. Gerstner, Jr., for whom the school is named.

… Friday, September 9, 2022 Paige Arnold , who will graduate from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) next spring, has been awarded the 2022 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Emeritus

A new drug delivery method could improve treatment of a lethal pediatric brain tumor called diffuse intrinsic pontine glioma.

… Friday, March 14, 2025 Brain tumors are one of the most difficult cancers to treat because of the blood-brain barrier, which protects the brain against toxins. That barrier also means treatments such as chemotherapy  can’t be delivered to tumors in high enough concentrations to be effective. As a result

The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general.

… Saturday, June 4, 2011 The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are

Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA (mRNA) can inactivate the functions of tumor suppressor genes and thereby promote cancer. The findings pinpoint previously unknown drivers of the disease, indicating that cancer diagnostics need to go beyond the analysis of DNA mutations.

… Monday, August 27, 2018 Bottom Line: Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA (mRNA) can inactivate the functions of tumor suppressor genes and thereby promote cancer. The findings pinpoint previously unknown drivers

Receiving five or more cycles of neoadjuvant chemotherapy was associated with worse progression-free survival (PFS) and overall survival (OS) compared to receiving three or four cycles — despite maximal surgical cytoreduction.

… Friday, November 13, 2020 Receiving five or more cycles of neoadjuvant chemotherapy was associated with worse progression-free survival (PFS) and overall survival (OS) compared to receiving three or four cycles — despite maximal cytoreduction — according to a retrospective analysis of patients with newly-diagnosed

Learn how new clinical trials at MSK are helping make cancer care at home a reality.

… Monday, June 3, 2024 Robert Daly, MD, MBA, a thoracic oncologist at Memorial Sloan Kettering, presented important new research about delivering high quality cancer care at home during the 2024 ASCO conference, the nation’s premier cancer conference. This research focuses on incorporating telemedicine

VEXAS syndrome is a confounding adult-onset inflammatory disease first described in 2020, which affects 1 in 4,000 men over 50. Now, MSK researchers are shedding new light on its mechanisms and laying the groundwork for potential targeted treatments.

… Monday, November 3, 2025 Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a confounding adult-onset inflammatory disease called VEXAS syndrome — shedding new light on its mechanisms and laying the groundwork for potential targeted

An MSK clinical trial found that participating in integrative therapy classes online could benefit cancer patients in active treatment, not only by reducing fatigue, anxiety, and depression but also lowering hospitalization rates.

… Tuesday, June 17, 2025 As Jan Gura prepared to face the onslaught of standard treatments for stage 2 ovarian cancer, she knew she also wanted integrative therapies that would help her feel better.  “I didn’t know how my body would respond to chemotherapy, but I’ve always been an active person. Being

En un ensayo clínico de MSK se descubrió que participar en clases de terapia integral en línea podría beneficiar a los pacientes que padecen cáncer y reciben tratamiento activo, no solo porque reduce la fatiga, la ansiedad y la depresión, sino también porque disminuye las tasas de hospitalización.

… Tuesday, June 17, 2025 Mientras Jan Gura se preparaba para enfrentarse a la avalancha de tratamientos estándar para el cáncer de ovario en estadio 2, sabía que también quería terapias integrales que la ayudaran a sentirse mejor.  “No sabía cómo respondería mi cuerpo a la quimioterapia, pero siempre he